Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Memantine Hydrochloride, a Low Affinity Antagonist to N-Methyl-D-Aspartate (NMDA) Type Receptors, in the Prevention of Cognitive Decline and Disease Progression in Down's Syndrome

NCT00240760 is registered in ClinicalTrials.gov with King's College London as lead sponsor.

NCT NCT00240760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00240760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Memantine Hydrochloride, a Low Affinity Antagonist to N-Methyl-D-Aspartate (NMDA) Type Receptors, in the Prevention of Cognitive Decline and Disease Progression in Down's Syndrome
Lead sponsor
King's College London
Phase
Not applicable
Overall status
Unknown status
Start date
October 31, 2005
Completion date
Not reported
Enrollment
180
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, down's syndrome, learning disabilities